Protocols

Hot on heels of a positive PhIII, Ablynx files $150M IPO; Shire sues Allergan over dry eye drug rivalry

→ After watching its European share price surge {$ABLX BB} yesterday on positive Phase III data, Ablynx feels it’s perfect timing for an IPO on Nasdaq. The Belgian biotech is looking to raise around $150 million at a time a growing number of European biotechs have been finding a warm welcome on the exchange. The group is pushing a new drug for acquired thrombotic thrombocytopenic purpura, or aTTP.

→ An increasingly litigious Shire has now sued Allergan, claiming the rival violated antitrust laws in blocking patients from receiving its dry eye disease drug.

→ Intra-Cellular Therapies $ITCI has raised $150 million from the sale of stock.


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Bulletin Healthcare

Immuno Oncology 360